• Publications
  • Influence
Whole–genome characterization of chemoresistant ovarian cancer
It is shown that gene breakage commonly inactivates the tumour suppressors RB1, NF1, RAD51B and PTEN in HGSC, and contributes to acquired chemotherapy resistance. Expand
Sofosbuvir and Velpatasvir for HCV in Patients with Decompensated Cirrhosis.
Treatment with sofosbuvir-velpatasvir with or without ribavirin for 12 weeks and with so-called "superdrugs" for 24 weeks resulted in high rates of sustained virologic response in patients with HCV infection and decompensated cirrhosis. Expand
Ledipasvir and Sofosbuvir Plus Ribavirin for Treatment of HCV Infection in Patients With Advanced Liver Disease.
The combination of ledipasvir, sofosbuvir, and ribavirin for 12 weeks produced high rates of SVR12 in patients with advanced liver disease, including those with decompensated cirrhosis before and after liver transplantation. Expand
Burden of liver disease in the United States: Summary of a workshop
Disease burden is a term that encompasses a number of aspects of the impact of a disease on the health of a population, ranging from (1) the frequency of the disease, as measured by incidence andExpand
Recommendations for the outpatient surveillance of renal transplant recipients. American Society of Transplantation.
These guidelines are applicable to all adult and pediatric renal transplant recipients, and they cover the outpatient screening for and prevention of diseases and complications that commonly occur after renal transplantation. Expand
Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma.
Significant clinical and biologic activity was observed for bevacizumab in nonmetastatic HCC and the primary study end point of 6-month progression-free survival was achieved. Expand
Sofosbuvir and ribavirin for treatment of compensated recurrent hepatitis C virus infection after liver transplantation.
Sustained virologic response 12 weeks after treatment was achieved by 28 of 40 patients, and Sofosbuvir and ribavirin combination therapy for 24 weeks is an effective and well-tolerated interferon-free treatment for post-transplantation HCV infection. Expand
Prospective, Randomized, Multicenter, Controlled Trial of a Bioartificial Liver in Treating Acute Liver Failure
This is the first prospective, randomized, controlled trial of an extracorporeal liver support system, demonstrating safety and improved survival in patients with fulminant/subfulminant hepatic failure. Expand
A survey of liver transplantation from living adult donors in the United States.
Adult-to-adult liver transplantation from a living donor is increasingly performed in the United States but is concentrated in a few large-volume centers. Expand
Hepatitis B virus genotypes in the United States: results of a nationwide study.
The study suggests that the epidemiology of HBV infection in the United States may have changed over time as a result of immigration from countries with a high prevalence ofHBV infection. Expand